Trends and outcomes in multicomponent blood transfusion: an 11‐year cohort study of a large multisite academic center

Abstract

BACKGROUND: Most studies reporting on blood component utilization overlook patients transfused with more than one type of blood product (multicomponent transfusion). These patients are of importance, as they are large consumers of blood products and likely have different characteristics and outcomes than nontransfused patients and patients transfused with only one blood component type. Our study aimed to determine the prevalence of multicomponent transfusion at a large multisite academic center, as well as the patient characteristics and outcomes associated with multicomponent transfusion. METHODS:A retrospective cohort study of transfused adult inpatients at the Ottawa Hospital between 2007 and 2017 was performed. Eligible transfusions were red blood cells (RBCs), platelets, plasma, cryoprecipitate, and/or fibrinogen concentrate. Descriptive analyses were done to determine multicomponent transfusion prevalence. Patient characteristics and outcomes associated with multicomponent transfusion were assessed using multivariable regressions. ABBREVIATIONS: aOR = adjusted odds ratio; FP = frozen plasma; FR = fibrinogen replacement; HOMR = Hospital-Patient One-Year Mortality Risk; LOS = length of stay; OHDW = Ottawa Hospital Data Warehouse; PLTs = platelets; TDM = Transfusion Data Mart.From the * Admissions with transfusions of any one type of blood component within 24 hours but not multicomponent transfusions. † P value from chi-square test, t test, or median test for categorical, continuous, or skewed continuous data, respectively. ‡ Internal medicine other than cardiology. § Surgery other than cardiac, vascular, and orthopedic surgeries. || The HOMR score was unavailable for admissions prior to April 2008; data shown are based on a total sample size of n = 49,889.